Expert Review of Cardiovascular Therapy最新文献_第7页

Safety of cardiovascular disease drugs approved between 2014 and 2021 in the US: a pharmacovigilance analysis. 2014年至2021年间美国批准的心血管疾病药物的安全性：药物警戒分析。

IF 2

Expert Review of Cardiovascular Therapy Pub Date : 2024-06-01 Epub Date: 2024-05-12 DOI: 10.1080/14779072.2024.2354255

Taehwan Park, Monica Hwang

{"title":"Safety of cardiovascular disease drugs approved between 2014 and 2021 in the US: a pharmacovigilance analysis.","authors":"Taehwan Park, Monica Hwang","doi":"10.1080/14779072.2024.2354255","DOIUrl":"10.1080/14779072.2024.2354255","url":null,"abstract":"Background: Recently FDA-approved drugs for cardiovascular disease (CVD) require robust post-marketing surveillance. The objective of this study was to assess their safety using a large pharmacovigilance database.Research design and methods: We analyzed adverse event (AE) reports for 17 drugs approved from 2014 to 2021, utilizing the FDA Adverse Event Reporting System (FAERS). Descriptive and disproportionality analyses were conducted by estimating the reporting odds ratio (ROR) and its 95% confidence interval.Results: Among the 43,664,773 AE reports 97,702 (0.22%) were related to newly approved CVD drugs. No AEs were reported for finerenone and evinacumab. The results from the disproportionality analyses revealed potential risks of acute kidney injury (ROR = 8.24, 95% CI: 6.05-11.22), cardiac failure (ROR = 4.80, 95% CI: 3.82-6.05), and hypotension (ROR = 3.98, 95% CI: 3.44-4.61) among sacubitril/valsartan users. Additionally, ivabradine was found to be associated with tachycardia (ROR = 11.94, 95% CI: 8.35-17.08), abnormal feeling (ROR = 4.40, 95% CI: 2.70-7.18), and dizziness (ROR = 2.56, 95% CI: 1.68-3.90).Conclusions: This study identified specific safety concerns related to recently approved CVD drugs. Further research is required to understand the underlying mechanisms and clinical implications of these findings.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"273-283"},"PeriodicalIF":2.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140897417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Role of anticoagulation in non-ST-elevation myocardial infarction: a contemporary narrative review. 抗凝治疗在非 ST 段抬高型心肌梗死中的作用：当代叙述性综述。

IF 2

Expert Review of Cardiovascular Therapy Pub Date : 2024-06-01 Epub Date: 2024-05-14 DOI: 10.1080/14779072.2024.2354243

Paul Jie Wen Tern, Khung Keong Yeo, Jack Wei Chieh Tan, Chee Tang Chin, Ru San Tan, Jonathan Yap

{"title":"Role of anticoagulation in non-ST-elevation myocardial infarction: a contemporary narrative review.","authors":"Paul Jie Wen Tern, Khung Keong Yeo, Jack Wei Chieh Tan, Chee Tang Chin, Ru San Tan, Jonathan Yap","doi":"10.1080/14779072.2024.2354243","DOIUrl":"10.1080/14779072.2024.2354243","url":null,"abstract":"Introduction: Anticoagulants play a vital role as part of the antithrombotic therapy of myocardial infarction and are complementary to antiplatelet therapies. In the acute setting, the rationale for their use is to antagonize the ongoing clotting cascade including during percutaneous coronary intervention. Anticoagulation may be an important part of the longer-term antithrombotic strategy especially in patients who have other existing indications (e.g. atrial fibrillation) for their use.Areas covered: In this narrative review, the authors provide a contemporary summary of the anticoagulation strategies of patients presenting with NSTEMI, both in terms of anticoagulation during the acute phase as well as suggested antithrombotic regimens for patients who require long-term anticoagulation for other indications.Expert opinion: Patients presenting with non-ST-elevation myocardial infarction (NSTEMI) should be initiated on anticoagulation (e.g. heparin/low molecular weight heparin) for the initial hospitalization period for those medically managed or until percutaneous coronary intervention. Longer term management of NSTEMI for patients with an existing indication for long-term anticoagulation should comprise triple antithrombotic therapy of anticoagulant (preferably DOAC) with aspirin and clopidogrel for up to 1 month (typically 1 week or until hospital discharge), followed by DOAC plus clopidogrel for up to 1 year, and then DOAC monotherapy thereafter.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"203-215"},"PeriodicalIF":2.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140915703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Managing chronic coronary syndrome: how do we achieve optimal patient outcomes? 管理慢性冠状动脉综合征：我们如何实现患者的最佳治疗效果？

IF 2

Expert Review of Cardiovascular Therapy Pub Date : 2024-06-01 Epub Date: 2024-05-20 DOI: 10.1080/14779072.2024.2357344

Antonis A Manolis, Theodora A Manolis, Antonis S Manolis

{"title":"Managing chronic coronary syndrome: how do we achieve optimal patient outcomes?","authors":"Antonis A Manolis, Theodora A Manolis, Antonis S Manolis","doi":"10.1080/14779072.2024.2357344","DOIUrl":"10.1080/14779072.2024.2357344","url":null,"abstract":"Introduction: Chronic coronary syndrome (CCS) remains the leading cause of death worldwide with high admission/re-admission rates. Medical databases were searched on CCS & its management.Areas covered: This review discusses phenotypes per stress-echocardiography, noninvasive/invasive testing (coronary computed-tomography angiography-CCTA; coronary artery calcium - CAC score; echocardiography assessing wall-motion, LV function, valvular disease; biomarkers), multidisciplinary management (risk factors/anti-inflammatory/anti-ischemic/antithrombotic therapies and revascularization), newer treatments (colchicine/ivabradine/ranolazine/melatonin), cardiac rehabilitation/exercise improving physical activity and quality-of-life, use of the implantable-defibrillator, and treatment with extracorporeal shockwave-revascularization for refractory symptoms.Expert opinion: CCS is age-dependent, leading cause of death worldwide with high hospitalization rates. Stress-echocardiography defines phenotypes and guides prophylaxis and management. CAC is a surrogate for atherosclerosis burden, best for patients of intermediate/borderline risk. Higher CAC-scores indicate more severe coronary abnormalities. CCTA is preferred for noninvasive detection of CAC and atherosclerosis burden, determining stenosis' functional significance, and guiding management. Combining CAC score with CCTA improves diagnostic yield and assists prognosis. Echocardiography assesses LV wall-motion and function and valvular disease. Biomarkers guide diagnosis/prognosis. CCS management is multidisciplinary: risk-factor management, anti-inflammatory/anti-ischemic/antithrombotic therapies, and revascularization. Newer therapies comprise colchicine, ivabradine, ranolazine, melatonin, glucagon-like peptide-1-receptor antagonists. Cardiac rehabilitation/exercise improves physical activity and quality-of-life. An ICD protects from sudden death. Extracorporeal shockwave-revascularization treats refractory symptoms.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"243-263"},"PeriodicalIF":2.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140956471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The best of 'best buys': public health values of potassium-enriched salt substitute. 最实惠 "中的 "最实惠"：富钾盐替代品的公共健康价值。

IF 2

Expert Review of Cardiovascular Therapy Pub Date : 2024-04-01 Epub Date: 2024-04-30 DOI: 10.1080/14779072.2024.2349105

Yangfeng Wu, Yifang Yuan

引用次数: 0

Cardiovascular disease and risk in COPD: a state of the art review. 慢性阻塞性肺病的心血管疾病和风险：最新研究综述。

IF 2

Expert Review of Cardiovascular Therapy Pub Date : 2024-04-01 Epub Date: 2024-03-27 DOI: 10.1080/14779072.2024.2333786

Ricardo Polman, John R Hurst, Omer Faruk Uysal, Swapna Mandal, Dominik Linz, Sami Simons

{"title":"Cardiovascular disease and risk in COPD: a state of the art review.","authors":"Ricardo Polman, John R Hurst, Omer Faruk Uysal, Swapna Mandal, Dominik Linz, Sami Simons","doi":"10.1080/14779072.2024.2333786","DOIUrl":"10.1080/14779072.2024.2333786","url":null,"abstract":"Introduction: Chronic Obstructive Pulmonary Disease (COPD) and cardiovascular diseases (CVD) commonly co-exist. Outcomes of people living with both conditions are poor in terms of symptom burden, receiving evidence-based treatment and mortality. Increased understanding of the underlying mechanisms may help to identify treatments to relieve this disease burden. This narrative review covers the overlap of COPD and CVD with a focus on clinical presentation, mechanisms, and interventions. Literature up to December 2023 are cited.Areas covered: 1. What is COPD 2. The co-existence of COPD and cardiovascular disease 3. Mechanisms of cardiovascular disease in COPD. 4. Populations with COPD are at risk of CVD 5. Complexity in the co-diagnosis of COPD in those with cardiovascular disease. 6. Therapy for COPD and implications for cardiovascular events and risk. 7. Cardiovascular risk and exacerbations of COPD. 8. Pro-active identification and management of CV risk in COPD.Expert opinion: The prospective identification of co-morbid COPD in CVD patients and of CVD and CV risk in people with COPD is crucial for optimizing clinical outcomes. This includes the identification of novel treatment targets and the design of clinical trials specifically designed to reduce the cardiovascular burden and mortality associated with COPD. Databases searched: Pubmed, 2006-2023.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"177-191"},"PeriodicalIF":2.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140287256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Why selective screening for asymptomatic carotid stenosis is currently appropriate: a special report. 为什么目前适合对无症状颈动脉狭窄进行选择性筛查：特别报告。

IF 1.8

Expert Review of Cardiovascular Therapy Pub Date : 2024-04-01 Epub Date: 2024-03-18 DOI: 10.1080/14779072.2024.2330660

Kosmas I Paraskevas, Alan Dardik, Marc L Schermerhorn, Christos D Liapis, Armando Mansilha, Brajesh K Lal, William A Gray, Martin M Brown, Piotr Myrcha, Carl J Lavie, Clark J Zeebregts, Eric A Secemsky, Luca Saba, Matthew Blecha, Victor Gurevich, Mauro Silvestrini, Ales Blinc, Alexei Svetlikov, Jose Fernandes E Fernandes, Peter A Schneider, Peter Gloviczki, Christopher J White, Ali F AbuRahma

{"title":"Why selective screening for asymptomatic carotid stenosis is currently appropriate: a special report.","authors":"Kosmas I Paraskevas, Alan Dardik, Marc L Schermerhorn, Christos D Liapis, Armando Mansilha, Brajesh K Lal, William A Gray, Martin M Brown, Piotr Myrcha, Carl J Lavie, Clark J Zeebregts, Eric A Secemsky, Luca Saba, Matthew Blecha, Victor Gurevich, Mauro Silvestrini, Ales Blinc, Alexei Svetlikov, Jose Fernandes E Fernandes, Peter A Schneider, Peter Gloviczki, Christopher J White, Ali F AbuRahma","doi":"10.1080/14779072.2024.2330660","DOIUrl":"10.1080/14779072.2024.2330660","url":null,"abstract":"Introduction: Two of the main reasons recent guidelines do not recommend routine population-wide screening programs for asymptomatic carotid artery stenosis (AsxCS) is that screening could lead to an increase of carotid revascularization procedures and that such mass screening programs may not be cost-effective. Nevertheless, selective screening for AsxCS could have several benefits. This article presents the rationale for such a program.Areas covered: The benefits of selective screening for AsxCS include early recognition of AsxCS allowing timely initiation of preventive measures to reduce future myocardial infarction (MI), stroke, cardiac death and cardiovascular (CV) event rates.Expert opinion: Mass screening programs for AsxCS are neither clinically effective nor cost-effective. Nevertheless, targeted screening of populations at high risk for AsxCS provides an opportunity to identify these individuals earlier rather than later and to initiate a number of lifestyle measures, risk factor modifications, and intensive medical therapy in order to prevent future strokes and CV events. For patients at 'higher risk of stroke' on best medical treatment, a prophylactic carotid intervention may be considered.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"159-165"},"PeriodicalIF":1.8,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140119190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Aveir VR leadless pacemaker: interview with professor Tom Wong. Aveir VR 无导线起搏器：Tom Wong 教授访谈。

IF 2

Expert Review of Cardiovascular Therapy Pub Date : 2024-04-01 Epub Date: 2024-05-09 DOI: 10.1080/14779072.2024.2340260

Tom Wong

引用次数: 0

How will coronary physiology, plaque vulnerability and ischemia be integrated in future patient pathways with chest pain? 如何将冠状动脉生理学、斑块易损性和缺血纳入未来胸痛患者的治疗路径？

IF 2

Expert Review of Cardiovascular Therapy Pub Date : 2024-04-01 Epub Date: 2024-04-28 DOI: 10.1080/14779072.2024.2347224

Richard J Jabbour, Nick Curzen

引用次数: 0

Angiographic patterns in spontaneous coronary artery dissection: novel diagnostic insights. 自发性冠状动脉夹层的血管造影模式：新的诊断见解。

IF 2

Expert Review of Cardiovascular Therapy Pub Date : 2024-04-01 Epub Date: 2024-05-02 DOI: 10.1080/14779072.2024.2349103

Marcos García-Guimarães, Teresa Bastante, David Del Val, Diego Fernández-Rodríguez, Teresa Guiberteau-Diaz, Jorge Salamanca, Fernando Rivero, Fernando Alfonso

引用次数: 0

Sex differences in trends and in-hospital outcomes of acute myocardial infarction in patients with familial hypercholesterolemia: insights from a large national database. 家族性高胆固醇血症患者急性心肌梗死的趋势和院内预后的性别差异：大型国家数据库的启示。

IF 2

Expert Review of Cardiovascular Therapy Pub Date : 2024-04-01 Epub Date: 2024-03-12 DOI: 10.1080/14779072.2024.2329720

Frederick Berro Rivera, Sung Whoy Cha, Mara Bernadette Liston, Sonny Redula, Nathan Ross B Bantayan, Nishant Shah, Mamas A Mamas, Annabelle Santos Volgman

{"title":"Sex differences in trends and in-hospital outcomes of acute myocardial infarction in patients with familial hypercholesterolemia: insights from a large national database.","authors":"Frederick Berro Rivera, Sung Whoy Cha, Mara Bernadette Liston, Sonny Redula, Nathan Ross B Bantayan, Nishant Shah, Mamas A Mamas, Annabelle Santos Volgman","doi":"10.1080/14779072.2024.2329720","DOIUrl":"10.1080/14779072.2024.2329720","url":null,"abstract":"Background: Sex differences in clinical outcomes following acute myocardial infarction (AMI) are well known. However, data on sex differences among patients with familial hypercholesterolemia (FH) are limited. We aimed to explore sex differences in outcomes of AMI among patients with FH from a national administrative dataset.Research design and methods: We utilized the National Inpatient Sample to identify admissions with a primary diagnosis of AMI and a secondary diagnosis of FH. Our primary outcome of interest was in-hospital mortality; secondary outcomes were performance of percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG), respiratory complications, use of inotropes, use of mechanical circulatory support (MCS), bleeding complications, transfusion and facility discharge. We adjusted for demographics (model A), comorbidities (model B), and intervention (model C).Results: Between October 2016 and December 2020, 5,714,993 admissions with a primary diagnosis of AMI were identified, of which 3,035 (0.05%) had a secondary diagnosis of FH. In-hospital mortality did not differ between men and women (Model C, adjusted OR = 0.85; 95% CI 0.28-2.60, p = 0.773). There was no sex difference in the secondary outcomes.Conclusion: Despite generally being older and having more comorbidities, women with FH fair equally with men with FH in terms of mortality during AMI admission.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"193-200"},"PeriodicalIF":2.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140068287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0